Clinical trial results:
A Phase 1/2a Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AFM24 in Combination with Atezolizumab in Patients with Selected Advanced/Metastatic EGFR-expressing Cancers

Summary

EudraCT number	2021-000707-20
Trial protocol	ES PL
Global end of trial date	11 June 2025

Results information

Result version number	v1 (current)
This version publication date	06 August 2025
First version publication date	06 August 2025

Trial information

Trial identification

Sponsor protocol code	AFM24-102

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT05109442
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Affimed GmbH
Sponsor organisation address	Gottlieb-Daimler-Straße 2, Mannheim, Germany, 68165
Public contact	Clinical Trial Manager, Affimed GmbH, +49 6221 6743-621, u.gaertner@affimed.com
Scientific contact	Clinical Trial Manager, Affimed GmbH, +49 6221 6743-621, u.gaertner@affimed.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	07 April 2025
Is this the analysis of the primary completion data?	Yes
Primary completion date	06 March 2025
Global end of trial reached?	Yes
Global end of trial date	11 June 2025
Was the trial ended prematurely?	Yes

Notes:

General information about the trial

Main objective of the trial:

Dose Escalation Phase (Phase 1):
-To determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of AFM24 in combination with atezolizumab.

Phase 2a:
-To evaluate the antitumor activity of AFM24 in combination with atezolizumab in terms of ORR.

Protection of trial subjects:

Subjects were considered eligible to be enrolled in the study only if all of the inclusion and none of the exclusion criteria were met. Subjects were qualified to receive the investigational treatment only if they were deemed eligible post the Safety Lead-in phase where they received a single i.v. AFM24 infusion on Day-7, and were then observed for any AE for 1 week.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	23 August 2021
Long term follow-up planned	Yes
Long term follow-up rationale	Safety, Efficacy
Long term follow-up duration	20 Months
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Poland: 23
Country: Number of subjects enrolled	Spain: 42
Country: Number of subjects enrolled	United Kingdom: 7
Country: Number of subjects enrolled	United States: 5
Country: Number of subjects enrolled	Korea, Republic of: 35
Worldwide total number of subjects	112
EEA total number of subjects	65

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37	0

wk	
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	52
From 65 to 84 years	60
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

This was an interventional, Phase 1/2a, Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AFM24 in Combination with Atezolizumab in subjects with documented histologically or cytologically confirmed select advanced or metastatic EGFR-positive cancers.

Pre-assignment

Screening details:

EXP-2 and EXP-3 subjects were pre-screened to assess EGFR expression. All subjects attended screening assessments that included review of subject's medical history, assessment of ECOG performance status, physical examination, ECG, laboratory assessments, tumor assessments and histopathology. Population of trial tables are based on the Safety set.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	AFM24 160 mg + atezolizumab 840 mg

Arm description:

Subjects with confirmed selected advanced or metastatic epidermal growth factor receptor (EGFR)-positive cancers were administered one dose of 160 milligram (mg) AFM24 once weekly via intravenous (i.v.) infusion. Approximately 1 hour before AFM24 infusion, subjects were required to receive the following premedications: dexamethasone, H1 antagonist and optionally a H2 antagonist, and acetaminophen. Subjects were also administered one dose of 840 mg atezolizumab once every two weeks via i.v. infusion. Subjects could receive the investigational treatment in recurring 4-week cycles until disease progression, intolerable toxicity, investigator discretion, or subject's withdrawal of consent, whichever occurred first. Subjects received treatment only if they did not have a Grade ≥3 cytokine release syndrome (CRS) or infusion-related reaction (IRR) or any other possible related Grade ≥3 treatment-emergent adverse events (TEAEs) after 1 dose of AFM24 (Safety Lead-in phase, Day -7 to Day -1).

Arm type	Experimental
Investigational medicinal product name	AFM24
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

One dose of 160 mg administered once weekly.

Investigational medicinal product name	Atezolizumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

One dose of 840 mg once every two weeks.

Arm title	AFM24 480 mg + atezolizumab 840 mg

Arm description:

Subjects with confirmed selected advanced or metastatic EGFR-positive cancers were administered one dose of 480 mg AFM24 once weekly via i.v. infusion. Approximately 1 hour before AFM24 infusion, subjects were required to receive the following premedications: dexamethasone, H1 antagonist and

optionally a H2 antagonist, and acetaminophen. Subjects were also administered one dose of 840 mg atezolizumab once every two weeks via i.v. infusion. Subjects could receive the investigational treatment in recurring 4-week cycles until disease progression, intolerable toxicity, investigator discretion, or subject's withdrawal of consent, whichever occurred first. Subjects received treatment only if they did not have a Grade ≥3 CRS or IRR or any other possible related Grade ≥3 TEAEs after 1 dose of AFM24 (Safety Lead-in phase, Day -7 to Day -1).

Arm type	Experimental
Investigational medicinal product name	AFM24
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

One dose of 480 mg administered once weekly.

Investigational medicinal product name	Atezolizumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

One dose of 840 mg once every two weeks.

Arm title	EXP-1: EGFR-WT NSCLC

Arm description:

Subjects with metastatic EGFR-wild type (EGFR-wt)-expressing non-small cell lung cancer (NSCLC) were administered one dose of 480 mg AFM24 once weekly via i.v. infusion. Approximately 1 hour before AFM24 infusion, subjects were required to receive the following premedications: dexamethasone, H1 antagonist and optionally a H2 antagonist, and acetaminophen. Subjects were also administered one dose of 840 mg atezolizumab once every two weeks via i.v. infusion. Subjects were treated in recurring 4-week cycles until disease progression, intolerable toxicity, death, or discontinuation from the study, whichever occurred first. Subjects received treatment only if they did not have a Grade ≥3 CRS or IRR or any other possible related Grade ≥3 TEAEs after 1 dose of AFM24 (Safety Lead-in phase, Day -7 to Day -1).

Arm type	Experimental
Investigational medicinal product name	AFM24
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

One dose of 480 mg administered once weekly.

Investigational medicinal product name	Atezolizumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

One dose of 840 mg once every two weeks.

Arm title	EXP-2: Gastric or GEJ adenocarcinoma

Arm description:

Subjects with locally advanced, unresectable, or metastatic gastric or gastro-esophageal junction (GEJ) adenocarcinoma were administered one dose of 480 mg AFM24 once weekly via i.v. infusion. Approximately 1 hour before AFM24 infusion, subjects were required to receive the following premedications: dexamethasone, H1 antagonist and optionally a H2 antagonist, and acetaminophen. Subjects were also administered one dose of 840 mg atezolizumab once every two weeks via i.v. infusion. Subjects were treated in recurring 4-week cycles until disease progression, intolerable toxicity,

death, or discontinuation from the study, whichever occurred first. Subjects received treatment only if they did not have a Grade ≥3 CRS or IRR or any other possible related Grade ≥3 TEAEs after 1 dose of AFM24 (Safety Lead-in phase, Day -7 to Day -1).

Arm type	Experimental
Investigational medicinal product name	AFM24
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

One dose of 480 mg administered once weekly.

Investigational medicinal product name	Atezolizumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

One dose of 840 mg once every two weeks.

Arm title	EXP-3: Carcinoma, Hepatobiliary or Pancreatic Adenocarcinoma

Arm description:

Subjects with advanced or metastatic hepatocellular carcinoma (other than fibrolamellar and sarcomatoid subtype, Barcelona Clinic Liver Cancer Stage C disease or Stage B disease not amenable to locoregional therapy or refractory to locoregional therapy), hepatobiliary or pancreatic adenocarcinoma, were administered one dose of 480 mg AFM24 once weekly via i.v. infusion. Approximately 1 hour before AFM24 infusion, subjects were required to receive the following premedications: dexamethasone, H1 antagonist and optionally a H2 antagonist, and acetaminophen. Subjects were also administered one dose of 840 mg atezolizumab once every two weeks via i.v. infusion. Subjects were treated in recurring 4-week cycles until disease progression, intolerable toxicity, death, or discontinuation from the study, whichever occurred first. Subjects received treatment only if they did not have a Grade ≥3 CRS or IRR or any other possible related Grade ≥3 TEAEs in the Safety Lead-in phase (Day -7 to Day -1).

Arm type	Experimental
Investigational medicinal product name	AFM24
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

One dose of 480 mg administered once weekly.

Investigational medicinal product name	Atezolizumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

One dose of 840 mg once every two weeks.

Arm title	EXP-4: EGFR mutated NSCLC

Arm description:

Subjects with advanced or metastatic NSCLC harboring a targetable EGFR kinase domain mutation were administered one dose of 480 mg AFM24 once weekly via i.v. infusion. Approximately 1 hour before AFM24 infusion, subjects were required to receive the following premedications: dexamethasone, H1 antagonist and optionally a H2 antagonist, and acetaminophen. Subjects were also administered one dose of 840 mg atezolizumab once every two weeks via i.v. infusion. Subjects were treated in recurring 4-week cycles until disease progression, intolerable toxicity, death, or discontinuation from the study, whichever occurred first. Subjects received treatment only if they did not have a Grade ≥3 CRS or IRR or any other possible related Grade ≥3 TEAEs after 1 dose of AFM24 (Safety Lead-in phase, Day -7 to Day -1).

Arm type	Experimental
Investigational medicinal product name	AFM24
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

One dose of 480 mg administered once weekly.

Investigational medicinal product name	Atezolizumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

One dose of 840 mg once every two weeks.

Number of subjects in period 1	AFM24 160 mg + atezolizumab 840 mg	AFM24 480 mg + atezolizumab 840 mg	EXP-1: EGFR-WT NSCLC
Started	4	6	49
Completed	0	0	0
Not completed	4	6	49
Consent withdrawn by subject	-	-	1
Adverse event, non-fatal	-	1	5
Death	-	-	4
Investigator’s decision	1	-	1
Other than listed	-	-	9
Disease Progression	3	5	29

Number of subjects in period 1	EXP-2: Gastric or GEJ adenocarcinoma	EXP-3: Carcinoma, Hepatobiliary or Pancreatic Adenocarcinoma	EXP-4: EGFR mutated NSCLC
Started	12	11	30
Completed	0	0	0
Not completed	12	11	30
Consent withdrawn by subject	-	-	-
Adverse event, non-fatal	-	-	2
Death	-	-	1
Investigator’s decision	-	-	2
Other than listed	2	-	8
Disease Progression	10	11	17

Baseline characteristics

Reporting groups

Reporting group title	AFM24 160 mg + atezolizumab 840 mg

Reporting group description:

Subjects with confirmed selected advanced or metastatic epidermal growth factor receptor (EGFR)-positive cancers were administered one dose of 160 milligram (mg) AFM24 once weekly via intravenous (i.v.) infusion. Approximately 1 hour before AFM24 infusion, subjects were required to receive the following premedications: dexamethasone, H1 antagonist and optionally a H2 antagonist, and acetaminophen. Subjects were also administered one dose of 840 mg atezolizumab once every two weeks via i.v. infusion. Subjects could receive the investigational treatment in recurring 4-week cycles until disease progression, intolerable toxicity, investigator discretion, or subject's withdrawal of consent, whichever occurred first. Subjects received treatment only if they did not have a Grade ≥3 cytokine release syndrome (CRS) or infusion-related reaction (IRR) or any other possible related Grade ≥3 treatment-emergent adverse events (TEAEs) after 1 dose of AFM24 (Safety Lead-in phase, Day -7 to Day -1).

Reporting group title	AFM24 480 mg + atezolizumab 840 mg

Reporting group description:

Subjects with confirmed selected advanced or metastatic EGFR-positive cancers were administered one dose of 480 mg AFM24 once weekly via i.v. infusion. Approximately 1 hour before AFM24 infusion, subjects were required to receive the following premedications: dexamethasone, H1 antagonist and optionally a H2 antagonist, and acetaminophen. Subjects were also administered one dose of 840 mg atezolizumab once every two weeks via i.v. infusion. Subjects could receive the investigational treatment in recurring 4-week cycles until disease progression, intolerable toxicity, investigator discretion, or subject's withdrawal of consent, whichever occurred first. Subjects received treatment only if they did not have a Grade ≥3 CRS or IRR or any other possible related Grade ≥3 TEAEs after 1 dose of AFM24 (Safety Lead-in phase, Day -7 to Day -1).

Reporting group title	EXP-1: EGFR-WT NSCLC

Reporting group description:

Subjects with metastatic EGFR-wild type (EGFR-wt)-expressing non-small cell lung cancer (NSCLC) were administered one dose of 480 mg AFM24 once weekly via i.v. infusion. Approximately 1 hour before AFM24 infusion, subjects were required to receive the following premedications: dexamethasone, H1 antagonist and optionally a H2 antagonist, and acetaminophen. Subjects were also administered one dose of 840 mg atezolizumab once every two weeks via i.v. infusion. Subjects were treated in recurring 4-week cycles until disease progression, intolerable toxicity, death, or discontinuation from the study, whichever occurred first. Subjects received treatment only if they did not have a Grade ≥3 CRS or IRR or any other possible related Grade ≥3 TEAEs after 1 dose of AFM24 (Safety Lead-in phase, Day -7 to Day -1).

Reporting group title	EXP-2: Gastric or GEJ adenocarcinoma

Reporting group description:

Subjects with locally advanced, unresectable, or metastatic gastric or gastro-esophageal junction (GEJ) adenocarcinoma were administered one dose of 480 mg AFM24 once weekly via i.v. infusion. Approximately 1 hour before AFM24 infusion, subjects were required to receive the following premedications: dexamethasone, H1 antagonist and optionally a H2 antagonist, and acetaminophen. Subjects were also administered one dose of 840 mg atezolizumab once every two weeks via i.v. infusion. Subjects were treated in recurring 4-week cycles until disease progression, intolerable toxicity, death, or discontinuation from the study, whichever occurred first. Subjects received treatment only if they did not have a Grade ≥3 CRS or IRR or any other possible related Grade ≥3 TEAEs after 1 dose of AFM24 (Safety Lead-in phase, Day -7 to Day -1).

Reporting group title	EXP-3: Carcinoma, Hepatobiliary or Pancreatic Adenocarcinoma

Reporting group description:

Subjects with advanced or metastatic hepatocellular carcinoma (other than fibrolamellar and sarcomatoid subtype, Barcelona Clinic Liver Cancer Stage C disease or Stage B disease not amenable to locoregional therapy or refractory to locoregional therapy), hepatobiliary or pancreatic adenocarcinoma, were administered one dose of 480 mg AFM24 once weekly via i.v. infusion. Approximately 1 hour before AFM24 infusion, subjects were required to receive the following premedications: dexamethasone, H1 antagonist and optionally a H2 antagonist, and acetaminophen. Subjects were also administered one dose of 840 mg atezolizumab once every two weeks via i.v. infusion. Subjects were treated in recurring 4-week cycles until disease progression, intolerable toxicity, death, or discontinuation from the study, whichever occurred first. Subjects received treatment only if they did not have a Grade ≥3 CRS or IRR or any other possible related Grade ≥3 TEAEs in the Safety Lead-in phase (Day -7 to Day -1).

Reporting group title	EXP-4: EGFR mutated NSCLC

Reporting group description:

Subjects with advanced or metastatic NSCLC harboring a targetable EGFR kinase domain mutation were administered one dose of 480 mg AFM24 once weekly via i.v. infusion. Approximately 1 hour before AFM24 infusion, subjects were required to receive the following premedications: dexamethasone, H1 antagonist and optionally a H2 antagonist, and acetaminophen. Subjects were also administered one dose of 840 mg atezolizumab once every two weeks via i.v. infusion. Subjects were treated in recurring 4-week cycles until disease progression, intolerable toxicity, death, or discontinuation from the study, whichever occurred first. Subjects received treatment only if they did not have a Grade ≥3 CRS or IRR or any other possible related Grade ≥3 TEAEs after 1 dose of AFM24 (Safety Lead-in phase, Day -7 to Day -1).

Reporting group values	AFM24 160 mg + atezolizumab 840 mg	AFM24 480 mg + atezolizumab 840 mg	EXP-1: EGFR-WT NSCLC
Number of subjects	4	6	49
Age categorical			
Safety Analysis Set: all subjects who received at least any amount of AFM24 or atezolizumab.			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	2	3	16
From 65-84 years	2	3	33
85 years and over	0	0	0
Age continuous			
Safety Analysis Set: all subjects who received at least any amount of AFM24 or atezolizumab.			
Units: years			
arithmetic mean	60.8	55.0	64.9
standard deviation	± 10.28	± 20.24	± 9.1
Gender categorical			
Safety Analysis Set: all subjects who received at least any amount of AFM24 or atezolizumab.			
Units: Subjects			
Female	4	4	13
Male	0	2	36
Race (NIH/OMB)			
Safety Analysis Set: all subjects who received at least any amount of AFM24 or atezolizumab.			
Units: Subjects			
American Indian or Alaska Native	0	0	0
Asian	0	0	18
Black or African American	0	0	1
Native Hawaiian or Other Pacific Islander	0	0	0
White	4	6	30
Unknown or Not Reported	0	0	0
Other	0	0	0
Ethnicity (NIH/OMB)			
Safety Analysis Set: all subjects who received at least any amount of AFM24 or atezolizumab.			
Units: Subjects			
Hispanic or Latino	0	0	0

Not Hispanic or Latino	4	6	45
Unknown or Not Reported	0	0	4

Reporting group values	EXP-2: Gastric or GEJ adenocarcinoma	EXP-3: Carcinoma, Hepatobiliary or Pancreatic Adenocarcinoma	EXP-4: EGFR mutated NSCLC
Number of subjects	12	11	30
Age categorical			
Safety Analysis Set: all subjects who received at least any amount of AFM24 or atezolizumab.			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	10	7	14
From 65-84 years	2	4	16
85 years and over	0	0	0
Age continuous			
Safety Analysis Set: all subjects who received at least any amount of AFM24 or atezolizumab.			
Units: years			
arithmetic mean	59.2	58.3	64.2
standard deviation	± 7.5	± 12.1	± 9.5
Gender categorical			
Safety Analysis Set: all subjects who received at least any amount of AFM24 or atezolizumab.			
Units: Subjects			
Female	3	7	20
Male	9	4	10
Race (NIH/OMB)			
Safety Analysis Set: all subjects who received at least any amount of AFM24 or atezolizumab.			
Units: Subjects			
American Indian or Alaska Native	0	0	0
Asian	0	1	18
Black or African American	0	0	0
Native Hawaiian or Other Pacific Islander	0	0	0
White	12	9	12
Unknown or Not Reported	0	1	0
Other	0	0	0
Ethnicity (NIH/OMB)			
Safety Analysis Set: all subjects who received at least any amount of AFM24 or atezolizumab.			
Units: Subjects			
Hispanic or Latino	0	0	0
Not Hispanic or Latino	12	10	30
Unknown or Not Reported	0	1	0

Reporting group values	Total		
Number of subjects	112		

Age categorical			
Safety Analysis Set: all subjects who received at least any amount of AFM24 or atezolizumab.			
Units: Subjects			
In utero	0		
Preterm newborn infants (gestational age < 37 wks)	0		
Newborns (0-27 days)	0		
Infants and toddlers (28 days-23 months)	0		
Children (2-11 years)	0		
Adolescents (12-17 years)	0		
Adults (18-64 years)	52		
From 65-84 years	60		
85 years and over	0		
Age continuous			
Safety Analysis Set: all subjects who received at least any amount of AFM24 or atezolizumab.			
Units: years			
arithmetic mean			
standard deviation	-		
Gender categorical			
Safety Analysis Set: all subjects who received at least any amount of AFM24 or atezolizumab.			
Units: Subjects			
Female	51		
Male	61		
Race (NIH/OMB)			
Safety Analysis Set: all subjects who received at least any amount of AFM24 or atezolizumab.			
Units: Subjects			
American Indian or Alaska Native	0		
Asian	37		
Black or African American	1		
Native Hawaiian or Other Pacific Islander	0		
White	73		
Unknown or Not Reported	1		
Other	0		
Ethnicity (NIH/OMB)			
Safety Analysis Set: all subjects who received at least any amount of AFM24 or atezolizumab.			
Units: Subjects			
Hispanic or Latino	0		
Not Hispanic or Latino	107		
Unknown or Not Reported	5		

End points

End points reporting groups

Reporting group title	AFM24 160 mg + atezolizumab 840 mg

Reporting group description:

Subjects with confirmed selected advanced or metastatic epidermal growth factor receptor (EGFR)-positive cancers were administered one dose of 160 milligram (mg) AFM24 once weekly via intravenous (i.v.) infusion. Approximately 1 hour before AFM24 infusion, subjects were required to receive the following premedications: dexamethasone, H1 antagonist and optionally a H2 antagonist, and acetaminophen. Subjects were also administered one dose of 840 mg atezolizumab once every two weeks via i.v. infusion. Subjects could receive the investigational treatment in recurring 4-week cycles until disease progression, intolerable toxicity, investigator discretion, or subject's withdrawal of consent, whichever occurred first. Subjects received treatment only if they did not have a Grade ≥3 cytokine release syndrome (CRS) or infusion-related reaction (IRR) or any other possible related Grade ≥3 treatment-emergent adverse events (TEAEs) after 1 dose of AFM24 (Safety Lead-in phase, Day -7 to Day -1).

Reporting group title	AFM24 480 mg + atezolizumab 840 mg

Reporting group description:

Subjects with confirmed selected advanced or metastatic EGFR-positive cancers were administered one dose of 480 mg AFM24 once weekly via i.v. infusion. Approximately 1 hour before AFM24 infusion, subjects were required to receive the following premedications: dexamethasone, H1 antagonist and optionally a H2 antagonist, and acetaminophen. Subjects were also administered one dose of 840 mg atezolizumab once every two weeks via i.v. infusion. Subjects could receive the investigational treatment in recurring 4-week cycles until disease progression, intolerable toxicity, investigator discretion, or subject's withdrawal of consent, whichever occurred first. Subjects received treatment only if they did not have a Grade ≥3 CRS or IRR or any other possible related Grade ≥3 TEAEs after 1 dose of AFM24 (Safety Lead-in phase, Day -7 to Day -1).

Reporting group title	EXP-1: EGFR-WT NSCLC

Reporting group description:

Subjects with metastatic EGFR-wild type (EGFR-wt)-expressing non-small cell lung cancer (NSCLC) were administered one dose of 480 mg AFM24 once weekly via i.v. infusion. Approximately 1 hour before AFM24 infusion, subjects were required to receive the following premedications: dexamethasone, H1 antagonist and optionally a H2 antagonist, and acetaminophen. Subjects were also administered one dose of 840 mg atezolizumab once every two weeks via i.v. infusion. Subjects were treated in recurring 4-week cycles until disease progression, intolerable toxicity, death, or discontinuation from the study, whichever occurred first. Subjects received treatment only if they did not have a Grade ≥3 CRS or IRR or any other possible related Grade ≥3 TEAEs after 1 dose of AFM24 (Safety Lead-in phase, Day -7 to Day -1).

Reporting group title	EXP-2: Gastric or GEJ adenocarcinoma

Reporting group description:

Subjects with locally advanced, unresectable, or metastatic gastric or gastro-esophageal junction (GEJ) adenocarcinoma were administered one dose of 480 mg AFM24 once weekly via i.v. infusion. Approximately 1 hour before AFM24 infusion, subjects were required to receive the following premedications: dexamethasone, H1 antagonist and optionally a H2 antagonist, and acetaminophen. Subjects were also administered one dose of 840 mg atezolizumab once every two weeks via i.v. infusion. Subjects were treated in recurring 4-week cycles until disease progression, intolerable toxicity, death, or discontinuation from the study, whichever occurred first. Subjects received treatment only if they did not have a Grade ≥3 CRS or IRR or any other possible related Grade ≥3 TEAEs after 1 dose of AFM24 (Safety Lead-in phase, Day -7 to Day -1).

Reporting group title	EXP-3: Carcinoma, Hepatobiliary or Pancreatic Adenocarcinoma

Reporting group description:

Subjects with advanced or metastatic hepatocellular carcinoma (other than fibrolamellar and sarcomatoid subtype, Barcelona Clinic Liver Cancer Stage C disease or Stage B disease not amenable to locoregional therapy or refractory to locoregional therapy), hepatobiliary or pancreatic adenocarcinoma, were administered one dose of 480 mg AFM24 once weekly via i.v. infusion. Approximately 1 hour before AFM24 infusion, subjects were required to receive the following premedications: dexamethasone, H1 antagonist and optionally a H2 antagonist, and acetaminophen. Subjects were also administered one dose of 840 mg atezolizumab once every two weeks via i.v. infusion. Subjects were treated in recurring 4-week cycles until disease progression, intolerable toxicity, death, or discontinuation from the study, whichever occurred first. Subjects received treatment only if they did not have a Grade ≥3 CRS or IRR or any other possible related Grade ≥3 TEAEs in the Safety Lead-in phase (Day -7 to Day -1).

Reporting group title	EXP-4: EGFR mutated NSCLC

Reporting group description:

Subjects with advanced or metastatic NSCLC harboring a targetable EGFR kinase domain mutation were administered one dose of 480 mg AFM24 once weekly via i.v. infusion. Approximately 1 hour before AFM24 infusion, subjects were required to receive the following premedications: dexamethasone, H1 antagonist and optionally a H2 antagonist, and acetaminophen. Subjects were also administered one dose of 840 mg atezolizumab once every two weeks via i.v. infusion. Subjects were treated in recurring 4-week cycles until disease progression, intolerable toxicity, death, or discontinuation from the study, whichever occurred first. Subjects received treatment only if they did not have a Grade ≥3 CRS or IRR or any other possible related Grade ≥3 TEAEs after 1 dose of AFM24 (Safety Lead-in phase, Day -7 to Day -1).

Primary: Phase 1 - Adverse events to be assessed by the incidence and severity of dose-limiting toxicity (DLT) within the DLT observation period (Cycle 1)

End point title	Phase 1 - Adverse events to be assessed by the incidence and severity of dose-limiting toxicity (DLT) within the DLT observation period (Cycle 1)[1][2]

End point description:

A DLT is defined as an adverse event (AE) or abnormal laboratory value assessed as unrelated to underlying disease, disease progression, inter-current illness, or concomitant medications, that occurs ≤28 days following the first dose of AFM24 in combination with atezolizumab and that meets any of the following criteria: ≥ Common Terminology Criteria for Adverse Events (CTCAE) Grade 4 neutropenia lasting for longer than 4 consecutive days; febrile neutropenia that does not resolve within 48 hours after start of antibiotics; CTCAE Grade 3 (associated with bleeding) or Grade 4 thrombocytopenia; ≥CTCAE Grade 4 anemia considered to be treatment related; any death at least possibly related to any study drug; any ≥CTCAE Grade 3 AE. Exceptions to the DLT criteria may apply. Dose-Determining Set (DDS): all subjects in the SAS who experienced DLT or met the minimum safety evaluation requirements without experiencing DLT during Cycle 1.

End point type	Primary

End point timeframe:

From first drug administration, until the end of the end of the Cycle 1, up to 28 days.

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: According to the Protocol, the endpoint was only analyzed descriptively.

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: According to the Protocol, the endpoint only considers subjects in the Phase 1.

End point values	AFM24 160 mg + atezolizumab 840 mg	AFM24 480 mg + atezolizumab 840 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	4	6		
Units: Count of subjects	0	1		

Statistical analyses

No statistical analyses for this end point

Primary: Phase 2a - Objective response rate according to RECIST v1.1 determined by Investigator assessment

End point title	Phase 2a - Objective response rate according to RECIST v1.1

	determined by Investigator assessment[3][4]

End point description:

Objective response rate (ORR) according to Response Evaluate Criteria in Solid Tumors (RECIST) v1.1 determined by Investigator assessment is reported as the proportion (percentage) of participants with the best response of complete response (CR), or partial response (PR) by RECIST v1.1 criteria. RECIST v1.1 for target lesions and assessed by computed tomography (CT) or (magnetic resonance imaging) MRI: CR, Disappearance of all target lesions; PR, ≥30% decrease in the sum of the longest diameter of target lesions; Overall Response = CR + PR. Full Analysis Set (FAS): all subjects who completed the Safety Lead-In phase and received any amount of any component of the combination treatments AFM24 and atezolizumab.

End point type	Primary

End point timeframe:

On Day 22 of Cycle 2, 4, 6, 8, 10, 12 and every 3 cycles thereafter, up to approximately 97 weeks.

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: According to the Protocol, the endpoint was only analyzed descriptively.

[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: According to the Protocol, the endpoint only considers subjects in the Phase 2a.

End point values	EXP-1: EGFR-WT NSCLC	EXP-2: Gastric or GEJ adenocarcinoma	EXP-3: Carcinoma, Hepatobiliary or Pancreatic Adenocarcinoma	EXP-4: EGFR mutated NSCLC
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	43	12	11	28
Units: Count of subjects	8	1	1	4

Statistical analyses

No statistical analyses for this end point

Secondary: Phase 1 - Objective response rate according to RECIST v1.1 determined by Investigator assessment

End point title	Phase 1 - Objective response rate according to RECIST v1.1 determined by Investigator assessment[5]

End point description:

Objective response rate (ORR) according to Response Evaluate Criteria in Solid Tumors (RECIST) v1.1 determined by Investigator assessment is reported as the proportion (percentage) of participants with the best response of complete response (CR), or partial response (PR) by RECIST v1.1 criteria. RECIST v1.1 for target lesions and assessed by computed tomography (CT) or (magnetic resonance imaging) MRI: CR, Disappearance of all target lesions; PR, ≥30% decrease in the sum of the longest diameter of target lesions; Overall Response = CR + PR. Full Analysis Set (FAS): all subjects who completed the Safety Lead-In phase and received any amount of any component of the combination treatments AFM24 and atezolizumab.

End point type	Secondary

End point timeframe:

On Day 22 of Cycle 2, 4, 6, 8, 10, 12 and every 3 cycles thereafter, up to 27 weeks.

Notes:

[5] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: According to the Protocol, the endpoint only considers subjects in the Phase 1.

End point values	AFM24 160 mg + atezolizumab 840 mg	AFM24 480 mg + atezolizumab 840 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3	6		
Units: Count of subjects	1	0		

Statistical analyses

No statistical analyses for this end point

Secondary: Phase 2a - Progression-Free Survival according to RECIST v1.1 by Investigator assessment

End point title	Phase 2a - Progression-Free Survival according to RECIST v1.1 by Investigator assessment[6]

End point description:

Progression-Free Survival (PFS) was determined as follows: (date of first progression or death [in the absence of progression] – date of first study drug injection)/30.4375. Subjects without progression or death were censored. Progression was defined using RECIST v1.1, as a 20% increase in the sum of the longest diameter of target lesions, or a measurable unequivocal increase in a non-target lesion, or the appearance of new lesion. Full Analysis Set (FAS): all subjects who completed the Safety Lead-In phase and received any amount of any component of the combination treatments AFM24 and atezolizumab.

End point type	Secondary

End point timeframe:

From Cycle 1 Day 1 until the date of disease progression or death from any cause, whichever occurs first, up to approximately 97 weeks.

Notes:

[6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: According to the Protocol, the endpoint only considers subjects in the Phase 2a.

End point values	EXP-1: EGFR-WT NSCLC	EXP-2: Gastric or GEJ adenocarcinoma	EXP-3: Carcinoma, Hepatobiliary or Pancreatic Adenocarcinoma	EXP-4: EGFR mutated NSCLC
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	43	12	11	28
Units: Month				
median (confidence interval 95%)	3.7454 (1.9055 to 5.848)	1.9384 (1.4784 to 8.7064)	1.9055 (0.9856 to 2.5298)	3.7125 (1.8727 to 7.4579)

Statistical analyses

No statistical analyses for this end point

Secondary: Phase 2a - Duration of Response according to RECIST v1.1 by Investigator assessment

End point title	Phase 2a - Duration of Response according to RECIST v1.1 by Investigator assessment[7]

End point description:

Duration of Response (DOR) was measured as follows: (date of first progression or death – date of first response [unconfirmed])/30.4375. Subjects without response were excluded from the analysis. Subjects without progression or death were censored. Response criteria (CR or PR) were defined using RECIST v1.1. Full Analysis Set (FAS): all subjects who completed the Safety Lead-In phase and received any amount of any component of the combination treatments AFM24 and atezolizumab. 9999 = Not enough events to calculate the data.

End point type	Secondary

End point timeframe:

From date of first response until progression or death, up to approximately 97 weeks.

Notes:

[7] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: According to the Protocol, the endpoint only considers subjects in the Phase 2a.

End point values	EXP-1: EGFR-WT NSCLC	EXP-2: Gastric or GEJ adenocarcinoma	EXP-3: Carcinoma, Hepatobiliary or Pancreatic Adenocarcinoma	EXP-4: EGFR mutated NSCLC
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	8	1	1	4
Units: Month				
median (confidence interval 95%)	9.20 (3.71 to 9999)	9999 (9999 to 9999)	3.71 (-9999 to 9999)	11.07 (6.54 to 9999)

Statistical analyses

No statistical analyses for this end point

Secondary: Phase 2a - Clinical benefit rate according to RECIST v1.1 by Investigator assessment

End point title	Phase 2a - Clinical benefit rate according to RECIST v1.1 by Investigator assessment[8]

End point description:

Clinical benefit rate (CBR) was measured per RECIST v1.1 criteria as the number of subjects who achieved overall tumor response (CR or PR) of any duration, or Stable Disease (SD) for at least 24 weeks. Full Analysis Set (FAS): all subjects who completed the Safety Lead-In phase and received any amount of any component of the combination treatments AFM24 and atezolizumab.

End point type	Secondary

End point timeframe:

On Day 22 of Cycle 2, 4, 6, 8, 10, 12 and every 3 cycles thereafter, up to approximately 97 weeks.

Notes:

[8] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: According to the Protocol, the endpoint only considers subjects in the Phase 2a.

End point values	EXP-1: EGFR-WT NSCLC	EXP-2: Gastric or GEJ adenocarcinoma	EXP-3: Carcinoma, Hepatobiliary or Pancreatic Adenocarcinoma	EXP-4: EGFR mutated NSCLC
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	43	12	11	28
Units: Count of subjects	11	2	1	8

Statistical analyses

No statistical analyses for this end point

Secondary: Phase 2a - Disease control rate according to RECIST v1.1 by Investigator assessment

End point title	Phase 2a - Disease control rate according to RECIST v1.1 by Investigator assessment[9]

End point description:

Disease control rate (DCR) was defined by achieving CR and/or PR and/or SD assessed by RECIST v1.1. Full Analysis Set (FAS): all subjects who completed the Safety Lead-In phase and received any amount of any component of the combination treatments AFM24 and atezolizumab.

End point type	Secondary

End point timeframe:

On Day 22 of Cycle 2, 4, 6, 8, 10, 12 and every 3 cycles thereafter, up to approximately 97 weeks.

Notes:

[9] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: According to the Protocol, the endpoint only considers subjects in the Phase 2a.

End point values	EXP-1: EGFR-WT NSCLC	EXP-2: Gastric or GEJ adenocarcinoma	EXP-3: Carcinoma, Hepatobiliary or Pancreatic Adenocarcinoma	EXP-4: EGFR mutated NSCLC
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	43	12	11	28
Units: Count of subjects	27	5	2	14

Statistical analyses

No statistical analyses for this end point

Secondary: Number of patients with Treatment-Emergent Adverse Events and Serious Adverse Events

End point title	Number of patients with Treatment-Emergent Adverse Events and Serious Adverse Events

End point description:

Number of patients with Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) is reported on the safety Analysis Set (all subjects who received at least any amount of AFM24 or atezolizumab).

End point type	Secondary

End point timeframe:

From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 100 weeks (phase 2a).

End point values	AFM24 160 mg + atezolizumab 840 mg	AFM24 480 mg + atezolizumab 840 mg	EXP-1: EGFR-WT NSCLC	EXP-2: Gastric or GEJ adenocarcinoma
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4	6	49	12
Units: Count of subjects				
Treatment-Emergent Adverse Events	4	6	49	11
Serious Adverse Events	2	3	30	6

End point values	EXP-3: Carcinoma, Hepatobiliary or Pancreatic Adenocarcinoma	EXP-4: EGFR mutated NSCLC		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	11	30		
Units: Count of subjects				
Treatment-Emergent Adverse Events	11	30		
Serious Adverse Events	7	15		

Statistical analyses

No statistical analyses for this end point

Secondary: Maximum concentration of AFM24 over the dosing interval (Cmax)

End point title	Maximum concentration of AFM24 over the dosing interval (Cmax)

End point description:

Maximum concentration of AFM24 over the dosing interval (Cmax) in Cycle 1 is reported based on the Pharmacokinetics (PK) set (all subjects who have received at least 1 adequately documented dose of AFM24 and have at least 1 adequately documented post dose PK measurement). Only subjects with available PK data are included in the analysis.

End point type	Secondary

End point timeframe:

Within 2 hours (h) prior to 1st drug infusion, at the end of first AFM24 infusion, 48 h and 144 h (Phase 1

only) after the end of first AFM24 infusion, within 2 h prior to the 2nd, 3rd and 4th drug infusion, and at the of the fourth AFM24 infusion.

End point values	AFM24 160 mg + atezolizumab 840 mg	AFM24 480 mg + atezolizumab 840 mg	EXP-1: EGFR-WT NSCLC	EXP-2: Gastric or GEJ adenocarcinoma
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	4	35	11
Units: nanogram/milliliter				
arithmetic mean (standard deviation)	73700 (± 25400)	269000 (± 61400)	207000 (± 78100)	207000 (± 73400)

End point values	EXP-3: Carcinoma, Hepatobiliary or Pancreatic Adenocarcinoma	EXP-4: EGFR mutated NSCLC		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	8	20		
Units: nanogram/milliliter				
arithmetic mean (standard deviation)	175000 (± 77200)	250000 (± 106000)		

Statistical analyses

No statistical analyses for this end point

Secondary: Time to maximum concentration of AFM24 over the dosing interval (Tmax)

End point title	Time to maximum concentration of AFM24 over the dosing interval (Tmax)

End point description:

Time to maximum concentration of AFM24 over the dosing interval (Tmax) in Cycle 1 is reported based on the Pharmacokinetics (PK) set (all subjects who have received at least 1 adequately documented dose of AFM24 and have at least 1 adequately documented post dose PK measurement). Only subjects with available PK data are included in the analysis.

End point type	Secondary

End point timeframe:

Within 2 hours (h) prior to 1st drug infusion, at the end of first AFM24 infusion, 48 h and 144 h (Phase 1 only) after the end of first AFM24 infusion, within 2 h prior to the 2nd, 3rd and 4th drug infusion, and at the of the fourth AFM24 infusion.

End point values	AFM24 160 mg + atezolizumab 840 mg	AFM24 480 mg + atezolizumab 840 mg	EXP-1: EGFR-WT NSCLC	EXP-2: Gastric or GEJ adenocarcinoma
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	4	35	11
Units: Hour (h)				
arithmetic mean (standard deviation)	3.15 (± 0.03)	3.15 (± 0.13)	9.78 (± 17.9)	27.9 (± 24.5)

End point values	EXP-3: Carcinoma, Hepatobiliary or Pancreatic Adenocarcinoma	EXP-4: EGFR mutated NSCLC		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	8	20		
Units: Hour (h)				
arithmetic mean (standard deviation)	8.63 (± 15.8)	10.6 (± 17.4)		

Statistical analyses

No statistical analyses for this end point

Secondary: Minimum concentration of AFM24 over the dosing interval (Cmin)

End point title	Minimum concentration of AFM24 over the dosing interval (Cmin)

End point description:

Minimum concentration of AFM24 over the dosing interval (Cmin), corresponding to trough concentration (Ctrough) levels at the end of the dosing interval, in Cycle 1 is reported based on the Pharmacokinetics (PK) set (all subjects who have received at least 1 adequately documented dose of AFM24 and have at least 1 adequately documented post dose PK measurement). Only subjects with available PK data are included in the analysis.

End point type	Secondary

End point timeframe:

Within 2 hours (h) prior to 1st drug infusion, at the end of first AFM24 infusion, 48 h and 144 h (Phase 1 only) after the end of first AFM24 infusion, within 2 h prior to the 2nd, 3rd and 4th drug infusion, and at the of the fourth AFM24 infusion.

End point values	AFM24 160 mg + atezolizumab 840 mg	AFM24 480 mg + atezolizumab 840 mg	EXP-1: EGFR-WT NSCLC	EXP-2: Gastric or GEJ adenocarcinoma
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	4	36	12
Units: nanogram/milliliter				
arithmetic mean (standard deviation)	16700 (± 12500)	105000 (± 37200)	56300 (± 48500)	73700 (± 40900)

End point values	EXP-3: Carcinoma, Hepatobiliary or Pancreatic Adenocarcinoma	EXP-4: EGFR mutated NSCLC		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	7	19		
Units: nanogram/milliliter				
arithmetic mean (standard deviation)	71900 (± 62500)	93700 (± 51600)		

Statistical analyses

No statistical analyses for this end point

Secondary: The area under the curve (AUC) of AFM24 from the time of dosing to 168 hours post dose (AUCtau)

End point title	The area under the curve (AUC) of AFM24 from the time of dosing to 168 hours post dose (AUCtau)

End point description:

The area under the curve (AUC) of AFM24 from the time of dosing to 168 hours post dose (AUCtau) in Cycle 1 is reported based on the Pharmacokinetics (PK) set (all subjects who have received at least 1 adequately documented dose of AFM24 and have at least 1 adequately documented post dose PK measurement). Only subjects with available PK data are included in the analysis.

End point type	Secondary

End point timeframe:

Within 2 hours (h) prior to 1st drug infusion, at the end of first AFM24 infusion, 48 h and 144 h (Phase 1 only) after the end of first AFM24 infusion, within 2 h prior to the 2nd, 3rd and 4th drug infusion, and at the of the fourth AFM24 infusion.

End point values	AFM24 160 mg + atezolizumab 840 mg	AFM24 480 mg + atezolizumab 840 mg	EXP-1: EGFR-WT NSCLC	EXP-2: Gastric or GEJ adenocarcinoma
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	31	11
Units: microgram*hour/milliliter				
arithmetic mean (standard deviation)	5760 (± 919)	27900 (± 9780)	19800 (± 9660)	21500 (± 8620)

End point values	EXP-3: Carcinoma, Hepatobiliary or Pancreatic	EXP-4: EGFR mutated NSCLC		

	Adenocarcinoma			
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	7	15		
Units: microgram*hour/milliliter				
arithmetic mean (standard deviation)	20500 (± 11400)	28600 (± 11900)		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of patients developing antidrug antibodies against AFM24

End point title	Number of patients developing antidrug antibodies against AFM24

End point description:

Number of patients developing antidrug antibodies (ADAs) against AFM24 is reported on the safety Analysis Set (all subjects who received at least any amount of AFM24 or atezolizumab).

End point type	Secondary

End point timeframe:

Phase 1: within 2h prior to each drug intake (Cycle 1), within 2 h prior to 1st and 3rd drug intake (Cycle 2 onwards) and at the End of Treatment (EOT), up to 27 weeks. Phase 2a: within 2h prior to 1st drug intake (each Cycle) and EOT, up to 97 weeks.

End point values	AFM24 160 mg + atezolizumab 840 mg	AFM24 480 mg + atezolizumab 840 mg	EXP-1: EGFR-WT NSCLC	EXP-2: Gastric or GEJ adenocarcinoma
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4	6	49	12
Units: Count of subjects	1	2	12	2

End point values	EXP-3: Carcinoma, Hepatobiliary or Pancreatic Adenocarcinoma	EXP-4: EGFR mutated NSCLC		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	11	30		
Units: Count of subjects	3	7		

Statistical analyses

No statistical analyses for this end point

Adverse events information

Timeframe for reporting adverse events:

From first drug administration up to 30 (TEAEs) or 56 (SAEs) days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 100 weeks (phase 2a).

Adverse event reporting additional description:

Safety Analysis Set: all subjects who received at least any amount of AFM24 or atezolizumab. Deaths were collected until the end of the study, up to approximately 100 weeks.

Assessment type	Systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	27.0

Reporting groups

Reporting group title	AFM24 160 mg + atezolizumab 840 mg

Reporting group description:

Subjects with confirmed selected advanced or metastatic epidermal growth factor receptor (EGFR)-positive cancers were administered one dose of 160 milligram (mg) AFM24 once weekly via intravenous (i.v.) infusion. Approximately 1 hour before AFM24 infusion, subjects were required to receive the following premedications: dexamethasone, H1 antagonist and optionally a H2 antagonist, and acetaminophen. Subjects were also administered one dose of 840 mg atezolizumab once every two weeks via i.v. infusion. Subjects could receive the investigational treatment in recurring 4-week cycles until disease progression, intolerable toxicity, investigator discretion, or subject's withdrawal of consent, whichever occurred first. Subjects received treatment only if they did not have a Grade ≥3 cytokine release syndrome (CRS) or infusion-related reaction (IRR) or any other possible related Grade ≥3 treatment-emergent adverse events (TEAEs) after 1 dose of AFM24 (Safety Lead-in phase, Day -7 to Day -1).

Reporting group title	AFM24 480 mg + atezolizumab 840 mg

Reporting group description:

Subjects with confirmed selected advanced or metastatic EGFR-positive cancers were administered one dose of 480 mg AFM24 once weekly via i.v. infusion. Approximately 1 hour before AFM24 infusion, subjects were required to receive the following premedications: dexamethasone, H1 antagonist and optionally a H2 antagonist, and acetaminophen. Subjects were also administered one dose of 840 mg atezolizumab once every two weeks via i.v. infusion. Subjects could receive the investigational treatment in recurring 4-week cycles until disease progression, intolerable toxicity, investigator discretion, or subject's withdrawal of consent, whichever occurred first. Subjects received treatment only if they did not have a Grade ≥3 CRS or IRR or any other possible related Grade ≥3 TEAEs after 1 dose of AFM24 (Safety Lead-in phase, Day -7 to Day -1).

Reporting group title	EXP-1: EGFR-WT NSCLC

Reporting group description:

Subjects with metastatic EGFR-wild type (EGFR-wt)-expressing non-small cell lung cancer (NSCLC) were administered one dose of 480 mg AFM24 once weekly via i.v. infusion. Approximately 1 hour before AFM24 infusion, subjects were required to receive the following premedications: dexamethasone, H1 antagonist and optionally a H2 antagonist, and acetaminophen. Subjects were also administered one dose of 840 mg atezolizumab once every two weeks via i.v. infusion. Subjects were treated in recurring 4-week cycles until disease progression, intolerable toxicity, death, or discontinuation from the study, whichever occurred first. Subjects received treatment only if they did not have a Grade ≥3 CRS or IRR or any other possible related Grade ≥3 TEAEs after 1 dose of AFM24 (Safety Lead-in phase, Day -7 to Day -1).

Reporting group title	EXP-2: Gastric or GEJ adenocarcinoma

Reporting group description:

Subjects with locally advanced, unresectable, or metastatic gastric or gastro-esophageal junction (GEJ) adenocarcinoma were administered one dose of 480 mg AFM24 once weekly via i.v. infusion. Approximately 1 hour before AFM24 infusion, subjects were required to receive the following premedications: dexamethasone, H1 antagonist and optionally a H2 antagonist, and acetaminophen. Subjects were also administered one dose of 840 mg atezolizumab once every two weeks via i.v. infusion. Subjects were treated in recurring 4-week cycles until disease progression, intolerable toxicity, death, or discontinuation from the study, whichever occurred first. Subjects received treatment only if they did not have a Grade ≥3 CRS or IRR or any other possible related Grade ≥3 TEAEs after 1 dose of

AFM24 (Safety Lead-in phase, Day -7 to Day -1).

Reporting group title	EXP-3: Carcinoma, Hepatobiliary or Pancreatic Adenocarcinoma

Reporting group description:

Subjects with advanced or metastatic hepatocellular carcinoma (other than fibrolamellar and sarcomatoid subtype, Barcelona Clinic Liver Cancer Stage C disease or Stage B disease not amenable to locoregional therapy or refractory to locoregional therapy), hepatobiliary or pancreatic adenocarcinoma, were administered one dose of 480 mg AFM24 once weekly via i.v. infusion. Approximately 1 hour before AFM24 infusion, subjects were required to receive the following premedications: dexamethasone, H1 antagonist and optionally a H2 antagonist, and acetaminophen. Subjects were also administered one dose of 840 mg atezolizumab once every two weeks via i.v. infusion. Subjects were treated in recurring 4-week cycles until disease progression, intolerable toxicity, death, or discontinuation from the study, whichever occurred first. Subjects received treatment only if they did not have a Grade ≥3 CRS or IRR or any other possible related Grade ≥3 TEAEs in the Safety Lead-in phase (Day -7 to Day -1).

Reporting group title	EXP-4: EGFR mutated NSCLC

Reporting group description:

Subjects with advanced or metastatic NSCLC harboring a targetable EGFR kinase domain mutation were administered one dose of 480 mg AFM24 once weekly via i.v. infusion. Approximately 1 hour before AFM24 infusion, subjects were required to receive the following premedications: dexamethasone, H1 antagonist and optionally a H2 antagonist, and acetaminophen. Subjects were also administered one dose of 840 mg atezolizumab once every two weeks via i.v. infusion. Subjects were treated in recurring 4-week cycles until disease progression, intolerable toxicity, death, or discontinuation from the study, whichever occurred first. Subjects received treatment only if they did not have a Grade ≥3 CRS or IRR or any other possible related Grade ≥3 TEAEs after 1 dose of AFM24 (Safety Lead-in phase, Day -7 to Day -1).

Serious adverse events	AFM24 160 mg + atezolizumab 840 mg	AFM24 480 mg + atezolizumab 840 mg	EXP-1: EGFR-WT NSCLC
Total subjects affected by serious adverse events			
subjects affected / exposed	2 / 4 (50.00%)	3 / 6 (50.00%)	30 / 49 (61.22%)
number of deaths (all causes)	3	5	21
number of deaths resulting from adverse events	0	0	5
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Tumour pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	1 / 49 (2.04%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cancer pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	1 / 49 (2.04%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tumour haemorrhage			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 49 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			

Pelvic venous thrombosis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 49 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Superior vena cava syndrome			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	1 / 49 (2.04%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	1 / 4 (25.00%)	1 / 6 (16.67%)	1 / 49 (2.04%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperthermia malignant			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	1 / 49 (2.04%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Multiple organ dysfunction syndrome			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 49 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 49 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Cytokine release syndrome			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	3 / 49 (6.12%)
occurrences causally related to treatment / all	0 / 0	0 / 0	3 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Vaginal prolapse			

subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 49 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Dyspnoea			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	4 / 49 (8.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 3
Pleural effusion			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	2 / 49 (4.08%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonitis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	2 / 49 (4.08%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 49 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sputum increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 49 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Organising pneumonia			
subjects affected / exposed	0 / 4 (0.00%)	1 / 6 (16.67%)	0 / 49 (0.00%)
occurrences causally related to treatment / all	0 / 0	3 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	2 / 49 (4.08%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Aspartate aminotransferase increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	2 / 49 (4.08%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood bilirubin increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	1 / 49 (2.04%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood alkaline phosphatase increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	1 / 49 (2.04%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gamma-glutamyltransferase increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	1 / 49 (2.04%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Infusion related reaction			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	3 / 49 (6.12%)
occurrences causally related to treatment / all	0 / 0	0 / 0	3 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fall			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 49 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal fracture			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 49 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Atrial fibrillation			

subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	1 / 49 (2.04%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac tamponade			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 49 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coronary artery disease			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	1 / 49 (2.04%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocardial infarction			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	1 / 49 (2.04%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Cerebrovascular accident			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	1 / 49 (2.04%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhage intracranial			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 49 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Seizure			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	1 / 49 (2.04%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subarachnoid haemorrhage			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	1 / 49 (2.04%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			

Febrile neutropenia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 49 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neutropenia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 49 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anaemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	1 / 49 (2.04%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anaemia of malignant disease			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 49 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Dysphagia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 49 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain upper			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 49 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Constipation			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	1 / 49 (2.04%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 49 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorder			

subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	1 / 49 (2.04%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestinal obstruction			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 49 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper gastrointestinal haemorrhage			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 49 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestinal obstruction			
subjects affected / exposed	1 / 4 (25.00%)	0 / 6 (0.00%)	0 / 49 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Jaundice cholestatic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 49 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 49 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain in extremity			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 49 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Pneumonia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	5 / 49 (10.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 6
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

COVID-19			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	2 / 49 (4.08%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumocystis jirovecii pneumonia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	2 / 49 (4.08%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Biliary sepsis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 49 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COVID-19 pneumonia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 49 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocarditis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	1 / 49 (2.04%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Escherichia bacteraemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	1 / 49 (2.04%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia sepsis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 49 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung abscess			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	1 / 49 (2.04%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peritonitis			

subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	1 / 49 (2.04%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Sepsis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	1 / 49 (2.04%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	0 / 4 (0.00%)	1 / 6 (16.67%)	0 / 49 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Hyponatraemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	1 / 49 (2.04%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypophagia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	1 / 49 (2.04%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	EXP-2: Gastric or GEJ adenocarcinoma	EXP-3: Carcinoma, Hepatobiliary or Pancreatic Adenocarcinoma	EXP-4: EGFR mutated NSCLC
Total subjects affected by serious adverse events			
subjects affected / exposed	6 / 12 (50.00%)	7 / 11 (63.64%)	15 / 30 (50.00%)
number of deaths (all causes)	9	9	9
number of deaths resulting from adverse events	0	1	2
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Tumour pain			
subjects affected / exposed	1 / 12 (8.33%)	0 / 11 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cancer pain			

subjects affected / exposed	0 / 12 (0.00%)	0 / 11 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tumour haemorrhage			
subjects affected / exposed	0 / 12 (0.00%)	1 / 11 (9.09%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Vascular disorders			
Pelvic venous thrombosis			
subjects affected / exposed	0 / 12 (0.00%)	1 / 11 (9.09%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Superior vena cava syndrome			
subjects affected / exposed	0 / 12 (0.00%)	0 / 11 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	0 / 12 (0.00%)	1 / 11 (9.09%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperthermia malignant			
subjects affected / exposed	0 / 12 (0.00%)	0 / 11 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Multiple organ dysfunction syndrome			
subjects affected / exposed	0 / 12 (0.00%)	0 / 11 (0.00%)	1 / 30 (3.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Pain			
subjects affected / exposed	0 / 12 (0.00%)	1 / 11 (9.09%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Immune system disorders			
Cytokine release syndrome			
subjects affected / exposed	0 / 12 (0.00%)	0 / 11 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Vaginal prolapse			
subjects affected / exposed	0 / 12 (0.00%)	0 / 11 (0.00%)	1 / 30 (3.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Dyspnoea			
subjects affected / exposed	0 / 12 (0.00%)	0 / 11 (0.00%)	1 / 30 (3.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleural effusion			
subjects affected / exposed	0 / 12 (0.00%)	0 / 11 (0.00%)	1 / 30 (3.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonitis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 11 (0.00%)	1 / 30 (3.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	0 / 12 (0.00%)	0 / 11 (0.00%)	1 / 30 (3.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Sputum increased			
subjects affected / exposed	0 / 12 (0.00%)	0 / 11 (0.00%)	1 / 30 (3.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Organising pneumonia			

subjects affected / exposed	0 / 12 (0.00%)	0 / 11 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	0 / 12 (0.00%)	0 / 11 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 12 (0.00%)	0 / 11 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood bilirubin increased			
subjects affected / exposed	0 / 12 (0.00%)	1 / 11 (9.09%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood alkaline phosphatase increased			
subjects affected / exposed	0 / 12 (0.00%)	0 / 11 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gamma-glutamyltransferase increased			
subjects affected / exposed	0 / 12 (0.00%)	0 / 11 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Infusion related reaction			
subjects affected / exposed	1 / 12 (8.33%)	0 / 11 (0.00%)	2 / 30 (6.67%)
occurrences causally related to treatment / all	1 / 1	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fall			

subjects affected / exposed	0 / 12 (0.00%)	0 / 11 (0.00%)	1 / 30 (3.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal fracture			
subjects affected / exposed	0 / 12 (0.00%)	0 / 11 (0.00%)	1 / 30 (3.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Atrial fibrillation			
subjects affected / exposed	0 / 12 (0.00%)	0 / 11 (0.00%)	1 / 30 (3.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac tamponade			
subjects affected / exposed	0 / 12 (0.00%)	0 / 11 (0.00%)	1 / 30 (3.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coronary artery disease			
subjects affected / exposed	0 / 12 (0.00%)	0 / 11 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocardial infarction			
subjects affected / exposed	0 / 12 (0.00%)	0 / 11 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Cerebrovascular accident			
subjects affected / exposed	0 / 12 (0.00%)	0 / 11 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhage intracranial			
subjects affected / exposed	0 / 12 (0.00%)	0 / 11 (0.00%)	1 / 30 (3.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Seizure			

subjects affected / exposed	0 / 12 (0.00%)	0 / 11 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subarachnoid haemorrhage			
subjects affected / exposed	0 / 12 (0.00%)	0 / 11 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Febrile neutropenia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 11 (0.00%)	3 / 30 (10.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	3 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neutropenia			
subjects affected / exposed	0 / 12 (0.00%)	1 / 11 (9.09%)	1 / 30 (3.33%)
occurrences causally related to treatment / all	0 / 0	1 / 1	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anaemia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 11 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anaemia of malignant disease			
subjects affected / exposed	0 / 12 (0.00%)	1 / 11 (9.09%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Dysphagia			
subjects affected / exposed	2 / 12 (16.67%)	0 / 11 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain upper			
subjects affected / exposed	1 / 12 (8.33%)	0 / 11 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Constipation			

subjects affected / exposed	0 / 12 (0.00%)	0 / 11 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	0 / 12 (0.00%)	0 / 11 (0.00%)	1 / 30 (3.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorder			
subjects affected / exposed	0 / 12 (0.00%)	0 / 11 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestinal obstruction			
subjects affected / exposed	1 / 12 (8.33%)	0 / 11 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper gastrointestinal haemorrhage			
subjects affected / exposed	1 / 12 (8.33%)	0 / 11 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestinal obstruction			
subjects affected / exposed	0 / 12 (0.00%)	0 / 11 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Jaundice cholestatic			
subjects affected / exposed	0 / 12 (0.00%)	1 / 11 (9.09%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	0 / 12 (0.00%)	0 / 11 (0.00%)	1 / 30 (3.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Pain in extremity			
subjects affected / exposed	0 / 12 (0.00%)	0 / 11 (0.00%)	1 / 30 (3.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Pneumonia			
subjects affected / exposed	1 / 12 (8.33%)	0 / 11 (0.00%)	1 / 30 (3.33%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COVID-19			
subjects affected / exposed	0 / 12 (0.00%)	0 / 11 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumocystis jirovecii pneumonia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 11 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Biliary sepsis			
subjects affected / exposed	0 / 12 (0.00%)	1 / 11 (9.09%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COVID-19 pneumonia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 11 (0.00%)	1 / 30 (3.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocarditis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 11 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia bacteraemia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 11 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia sepsis			

subjects affected / exposed	1 / 12 (8.33%)	0 / 11 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung abscess			
subjects affected / exposed	0 / 12 (0.00%)	0 / 11 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peritonitis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 11 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 11 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	0 / 12 (0.00%)	0 / 11 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Hyponatraemia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 11 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypophagia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 11 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	AFM24 160 mg + atezolizumab 840 mg	AFM24 480 mg + atezolizumab 840 mg	EXP-1: EGFR-WT NSCLC
Total subjects affected by non-serious adverse events			
subjects affected / exposed	4 / 4 (100.00%)	6 / 6 (100.00%)	48 / 49 (97.96%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Tumour pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	3 / 49 (6.12%)
occurrences (all)	0	0	3
Cancer pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	3 / 49 (6.12%)
occurrences (all)	0	0	4
Vascular disorders			
Haematoma			
subjects affected / exposed	0 / 4 (0.00%)	1 / 6 (16.67%)	0 / 49 (0.00%)
occurrences (all)	0	1	0
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	1 / 4 (25.00%)	1 / 6 (16.67%)	7 / 49 (14.29%)
occurrences (all)	1	1	9
Fatigue			
subjects affected / exposed	0 / 4 (0.00%)	2 / 6 (33.33%)	8 / 49 (16.33%)
occurrences (all)	0	2	9
Pyrexia			
subjects affected / exposed	1 / 4 (25.00%)	1 / 6 (16.67%)	5 / 49 (10.20%)
occurrences (all)	1	1	5
Chest pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	2 / 49 (4.08%)
occurrences (all)	0	0	2
Chills			
subjects affected / exposed	0 / 4 (0.00%)	1 / 6 (16.67%)	1 / 49 (2.04%)
occurrences (all)	0	1	1
Oedema peripheral			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 49 (0.00%)
occurrences (all)	0	0	0
Malaise			

subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 49 (0.00%)
occurrences (all)	0	0	0
Swelling			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 49 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	1 / 4 (25.00%)	1 / 6 (16.67%)	5 / 49 (10.20%)
occurrences (all)	1	1	6
Dyspnoea			
subjects affected / exposed	1 / 4 (25.00%)	1 / 6 (16.67%)	4 / 49 (8.16%)
occurrences (all)	1	1	5
Pleural effusion			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	3 / 49 (6.12%)
occurrences (all)	0	0	4
Catarrh			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 49 (0.00%)
occurrences (all)	0	0	0
Dysphonia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 49 (0.00%)
occurrences (all)	0	0	0
Psychiatric disorders			
Insomnia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	1 / 49 (2.04%)
occurrences (all)	0	0	1
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	1 / 4 (25.00%)	3 / 6 (50.00%)	10 / 49 (20.41%)
occurrences (all)	2	5	15
Aspartate aminotransferase increased			
subjects affected / exposed	1 / 4 (25.00%)	3 / 6 (50.00%)	8 / 49 (16.33%)
occurrences (all)	1	3	12
Neutrophil count decreased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	2 / 49 (4.08%)
occurrences (all)	0	0	2
Amylase increased			

subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	3 / 49 (6.12%)
occurrences (all)	0	0	4
Gamma-glutamyltransferase increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	2 / 49 (4.08%)
occurrences (all)	0	0	2
Lipase increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	3 / 49 (6.12%)
occurrences (all)	0	0	4
Weight decreased			
subjects affected / exposed	0 / 4 (0.00%)	1 / 6 (16.67%)	3 / 49 (6.12%)
occurrences (all)	0	1	4
Bilirubin conjugated increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 49 (0.00%)
occurrences (all)	0	0	0
Blood bilirubin increased			
subjects affected / exposed	1 / 4 (25.00%)	0 / 6 (0.00%)	0 / 49 (0.00%)
occurrences (all)	1	0	0
Lymphocyte count decreased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 49 (0.00%)
occurrences (all)	0	0	0
Waist circumference increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 49 (0.00%)
occurrences (all)	0	0	0
White blood cells urine positive			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 49 (0.00%)
occurrences (all)	0	0	0
Heart rate decreased			
subjects affected / exposed	0 / 4 (0.00%)	1 / 6 (16.67%)	0 / 49 (0.00%)
occurrences (all)	0	1	0
Injury, poisoning and procedural complications			
Infusion related reaction			
subjects affected / exposed	2 / 4 (50.00%)	5 / 6 (83.33%)	25 / 49 (51.02%)
occurrences (all)	3	6	31
Medication error			

subjects affected / exposed	1 / 4 (25.00%)	0 / 6 (0.00%)	2 / 49 (4.08%)
occurrences (all)	1	0	2
Procedural pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 49 (0.00%)
occurrences (all)	0	0	0
Radiation mucositis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 49 (0.00%)
occurrences (all)	0	0	0
Tendon rupture			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 49 (0.00%)
occurrences (all)	0	0	0
Nervous system disorders			
Headache			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	4 / 49 (8.16%)
occurrences (all)	0	0	11
Paraesthesia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	2 / 49 (4.08%)
occurrences (all)	0	0	12
Dizziness			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	1 / 49 (2.04%)
occurrences (all)	0	0	1
Blood and lymphatic system disorders			
Neutropenia			
subjects affected / exposed	2 / 4 (50.00%)	1 / 6 (16.67%)	4 / 49 (8.16%)
occurrences (all)	6	3	8
Anaemia			
subjects affected / exposed	2 / 4 (50.00%)	0 / 6 (0.00%)	3 / 49 (6.12%)
occurrences (all)	5	0	3
Lymphopenia			
subjects affected / exposed	3 / 4 (75.00%)	2 / 6 (33.33%)	3 / 49 (6.12%)
occurrences (all)	25	3	4
Leukopenia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 49 (0.00%)
occurrences (all)	0	0	0
Thrombocytopenia			

subjects affected / exposed	1 / 4 (25.00%)	0 / 6 (0.00%)	0 / 49 (0.00%)
occurrences (all)	3	0	0
Increased tendency to bruise			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 49 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	3 / 49 (6.12%)
occurrences (all)	0	0	6
Constipation			
subjects affected / exposed	0 / 4 (0.00%)	1 / 6 (16.67%)	2 / 49 (4.08%)
occurrences (all)	0	1	3
Nausea			
subjects affected / exposed	0 / 4 (0.00%)	3 / 6 (50.00%)	5 / 49 (10.20%)
occurrences (all)	0	5	8
Dyspepsia			
subjects affected / exposed	0 / 4 (0.00%)	1 / 6 (16.67%)	3 / 49 (6.12%)
occurrences (all)	0	1	3
Abdominal pain			
subjects affected / exposed	0 / 4 (0.00%)	2 / 6 (33.33%)	2 / 49 (4.08%)
occurrences (all)	0	2	2
Vomiting			
subjects affected / exposed	0 / 4 (0.00%)	2 / 6 (33.33%)	1 / 49 (2.04%)
occurrences (all)	0	2	1
Ascites			
subjects affected / exposed	3 / 4 (75.00%)	2 / 6 (33.33%)	0 / 49 (0.00%)
occurrences (all)	8	3	0
Dry mouth			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	1 / 49 (2.04%)
occurrences (all)	0	0	1
Abdominal pain upper			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 49 (0.00%)
occurrences (all)	0	0	0
Dysphagia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 49 (0.00%)
occurrences (all)	0	0	0

Upper gastrointestinal haemorrhage subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 6 (0.00%) 0	0 / 49 (0.00%) 0
Hepatobiliary disorders Jaundice subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 6 (0.00%) 0	0 / 49 (0.00%) 0
Jaundice cholestatic subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 6 (0.00%) 0	0 / 49 (0.00%) 0
Skin and subcutaneous tissue disorders Pruritus subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 6 (16.67%) 2	3 / 49 (6.12%) 3
Rash subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	2 / 6 (33.33%) 2	3 / 49 (6.12%) 4
Dermatitis acneiform subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 6 (0.00%) 0	2 / 49 (4.08%) 2
Nail disorder subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 6 (0.00%) 0	1 / 49 (2.04%) 1
Acne subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 6 (0.00%) 0	0 / 49 (0.00%) 0
Perioral dermatitis subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 6 (0.00%) 0	0 / 49 (0.00%) 0
Rash erythematous subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 6 (16.67%) 1	1 / 49 (2.04%) 1
Skin maceration subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 6 (0.00%) 0	0 / 49 (0.00%) 0
Musculoskeletal and connective tissue disorders			

Back pain			
subjects affected / exposed	0 / 4 (0.00%)	1 / 6 (16.67%)	2 / 49 (4.08%)
occurrences (all)	0	1	2
Arthralgia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	4 / 49 (8.16%)
occurrences (all)	0	0	7
Pain in extremity			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	2 / 49 (4.08%)
occurrences (all)	0	0	2
Myalgia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 49 (0.00%)
occurrences (all)	0	0	0
Muscular weakness			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 49 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
Upper respiratory tract infection			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	3 / 49 (6.12%)
occurrences (all)	0	0	3
Herpes zoster			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	1 / 49 (2.04%)
occurrences (all)	0	0	2
Rash pustular			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	2 / 49 (4.08%)
occurrences (all)	0	0	5
COVID-19			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	1 / 49 (2.04%)
occurrences (all)	0	0	1
Urinary tract infection			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 49 (0.00%)
occurrences (all)	0	0	0
Viral infection			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 49 (0.00%)
occurrences (all)	0	0	0
Otitis media			

subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 49 (0.00%)
occurrences (all)	0	0	0
Sinusitis			
subjects affected / exposed	0 / 4 (0.00%)	1 / 6 (16.67%)	0 / 49 (0.00%)
occurrences (all)	0	1	0
Candida infection			
subjects affected / exposed	0 / 4 (0.00%)	1 / 6 (16.67%)	0 / 49 (0.00%)
occurrences (all)	0	1	0
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	1 / 4 (25.00%)	2 / 6 (33.33%)	4 / 49 (8.16%)
occurrences (all)	2	3	7
Hyperkalaemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	4 / 49 (8.16%)
occurrences (all)	0	0	5
Hypocalcaemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	2 / 49 (4.08%)
occurrences (all)	0	0	3
Hyponatraemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	4 / 49 (8.16%)
occurrences (all)	0	0	5
Diabetes mellitus			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	3 / 49 (6.12%)
occurrences (all)	0	0	3
Hypokalaemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 49 (0.00%)
occurrences (all)	0	0	0
Hypophosphataemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	2 / 49 (4.08%)
occurrences (all)	0	0	4
Hyperglycaemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 49 (0.00%)
occurrences (all)	0	0	0

Non-serious adverse events	EXP-2: Gastric or GEJ adenocarcinoma	EXP-3: Carcinoma, Hepatobiliary or Pancreatic Adenocarcinoma	EXP-4: EGFR mutated NSCLC

Total subjects affected by non-serious adverse events			
subjects affected / exposed	11 / 12 (91.67%)	11 / 11 (100.00%)	29 / 30 (96.67%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Tumour pain			
subjects affected / exposed	0 / 12 (0.00%)	0 / 11 (0.00%)	2 / 30 (6.67%)
occurrences (all)	0	0	2
Cancer pain			
subjects affected / exposed	0 / 12 (0.00%)	1 / 11 (9.09%)	0 / 30 (0.00%)
occurrences (all)	0	1	0
Vascular disorders			
Haematoma			
subjects affected / exposed	0 / 12 (0.00%)	0 / 11 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	5 / 12 (41.67%)	8 / 11 (72.73%)	5 / 30 (16.67%)
occurrences (all)	9	13	6
Fatigue			
subjects affected / exposed	1 / 12 (8.33%)	0 / 11 (0.00%)	4 / 30 (13.33%)
occurrences (all)	1	0	4
Pyrexia			
subjects affected / exposed	1 / 12 (8.33%)	2 / 11 (18.18%)	3 / 30 (10.00%)
occurrences (all)	1	3	3
Chest pain			
subjects affected / exposed	1 / 12 (8.33%)	0 / 11 (0.00%)	0 / 30 (0.00%)
occurrences (all)	1	0	0
Chills			
subjects affected / exposed	0 / 12 (0.00%)	2 / 11 (18.18%)	0 / 30 (0.00%)
occurrences (all)	0	2	0
Oedema peripheral			
subjects affected / exposed	2 / 12 (16.67%)	1 / 11 (9.09%)	0 / 30 (0.00%)
occurrences (all)	2	1	0
Malaise			
subjects affected / exposed	1 / 12 (8.33%)	0 / 11 (0.00%)	0 / 30 (0.00%)
occurrences (all)	1	0	0
Swelling			

subjects affected / exposed	0 / 12 (0.00%)	1 / 11 (9.09%)	0 / 30 (0.00%)
occurrences (all)	0	1	0
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	0 / 12 (0.00%)	0 / 11 (0.00%)	5 / 30 (16.67%)
occurrences (all)	0	0	5
Dyspnoea			
subjects affected / exposed	1 / 12 (8.33%)	1 / 11 (9.09%)	3 / 30 (10.00%)
occurrences (all)	1	1	3
Pleural effusion			
subjects affected / exposed	0 / 12 (0.00%)	0 / 11 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Catarrh			
subjects affected / exposed	1 / 12 (8.33%)	0 / 11 (0.00%)	0 / 30 (0.00%)
occurrences (all)	1	0	0
Dysphonia			
subjects affected / exposed	0 / 12 (0.00%)	1 / 11 (9.09%)	0 / 30 (0.00%)
occurrences (all)	0	1	0
Psychiatric disorders			
Insomnia			
subjects affected / exposed	1 / 12 (8.33%)	1 / 11 (9.09%)	3 / 30 (10.00%)
occurrences (all)	1	1	3
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	3 / 12 (25.00%)	0 / 11 (0.00%)	6 / 30 (20.00%)
occurrences (all)	6	0	15
Aspartate aminotransferase increased			
subjects affected / exposed	3 / 12 (25.00%)	1 / 11 (9.09%)	6 / 30 (20.00%)
occurrences (all)	6	2	25
Neutrophil count decreased			
subjects affected / exposed	0 / 12 (0.00%)	0 / 11 (0.00%)	5 / 30 (16.67%)
occurrences (all)	0	0	13
Amylase increased			
subjects affected / exposed	0 / 12 (0.00%)	0 / 11 (0.00%)	2 / 30 (6.67%)
occurrences (all)	0	0	4
Gamma-glutamyltransferase			

increased			
subjects affected / exposed	0 / 12 (0.00%)	0 / 11 (0.00%)	3 / 30 (10.00%)
occurrences (all)	0	0	6
Lipase increased			
subjects affected / exposed	0 / 12 (0.00%)	0 / 11 (0.00%)	1 / 30 (3.33%)
occurrences (all)	0	0	3
Weight decreased			
subjects affected / exposed	0 / 12 (0.00%)	0 / 11 (0.00%)	1 / 30 (3.33%)
occurrences (all)	0	0	2
Bilirubin conjugated increased			
subjects affected / exposed	0 / 12 (0.00%)	1 / 11 (9.09%)	0 / 30 (0.00%)
occurrences (all)	0	2	0
Blood bilirubin increased			
subjects affected / exposed	0 / 12 (0.00%)	1 / 11 (9.09%)	0 / 30 (0.00%)
occurrences (all)	0	3	0
Lymphocyte count decreased			
subjects affected / exposed	0 / 12 (0.00%)	1 / 11 (9.09%)	0 / 30 (0.00%)
occurrences (all)	0	3	0
Waist circumference increased			
subjects affected / exposed	0 / 12 (0.00%)	1 / 11 (9.09%)	0 / 30 (0.00%)
occurrences (all)	0	1	0
White blood cells urine positive			
subjects affected / exposed	0 / 12 (0.00%)	1 / 11 (9.09%)	0 / 30 (0.00%)
occurrences (all)	0	1	0
Heart rate decreased			
subjects affected / exposed	0 / 12 (0.00%)	0 / 11 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Injury, poisoning and procedural complications			
Infusion related reaction			
subjects affected / exposed	9 / 12 (75.00%)	8 / 11 (72.73%)	19 / 30 (63.33%)
occurrences (all)	11	9	20
Medication error			
subjects affected / exposed	0 / 12 (0.00%)	1 / 11 (9.09%)	0 / 30 (0.00%)
occurrences (all)	0	1	0
Procedural pain			

subjects affected / exposed	0 / 12 (0.00%)	1 / 11 (9.09%)	0 / 30 (0.00%)
occurrences (all)	0	1	0
Radiation mucositis			
subjects affected / exposed	0 / 12 (0.00%)	1 / 11 (9.09%)	0 / 30 (0.00%)
occurrences (all)	0	1	0
Tendon rupture			
subjects affected / exposed	0 / 12 (0.00%)	1 / 11 (9.09%)	0 / 30 (0.00%)
occurrences (all)	0	1	0
Nervous system disorders			
Headache			
subjects affected / exposed	0 / 12 (0.00%)	0 / 11 (0.00%)	2 / 30 (6.67%)
occurrences (all)	0	0	2
Paraesthesia			
subjects affected / exposed	0 / 12 (0.00%)	1 / 11 (9.09%)	3 / 30 (10.00%)
occurrences (all)	0	1	3
Dizziness			
subjects affected / exposed	0 / 12 (0.00%)	0 / 11 (0.00%)	2 / 30 (6.67%)
occurrences (all)	0	0	2
Blood and lymphatic system disorders			
Neutropenia			
subjects affected / exposed	1 / 12 (8.33%)	0 / 11 (0.00%)	5 / 30 (16.67%)
occurrences (all)	16	0	8
Anaemia			
subjects affected / exposed	1 / 12 (8.33%)	3 / 11 (27.27%)	2 / 30 (6.67%)
occurrences (all)	8	5	2
Lymphopenia			
subjects affected / exposed	0 / 12 (0.00%)	2 / 11 (18.18%)	0 / 30 (0.00%)
occurrences (all)	0	4	0
Leukopenia			
subjects affected / exposed	0 / 12 (0.00%)	2 / 11 (18.18%)	1 / 30 (3.33%)
occurrences (all)	0	2	1
Thrombocytopenia			
subjects affected / exposed	0 / 12 (0.00%)	2 / 11 (18.18%)	0 / 30 (0.00%)
occurrences (all)	0	2	0
Increased tendency to bruise			

subjects affected / exposed	0 / 12 (0.00%)	1 / 11 (9.09%)	0 / 30 (0.00%)
occurrences (all)	0	2	0
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	3 / 12 (25.00%)	5 / 11 (45.45%)	3 / 30 (10.00%)
occurrences (all)	4	7	3
Constipation			
subjects affected / exposed	1 / 12 (8.33%)	2 / 11 (18.18%)	4 / 30 (13.33%)
occurrences (all)	1	3	4
Nausea			
subjects affected / exposed	1 / 12 (8.33%)	1 / 11 (9.09%)	0 / 30 (0.00%)
occurrences (all)	1	1	0
Dyspepsia			
subjects affected / exposed	0 / 12 (0.00%)	2 / 11 (18.18%)	1 / 30 (3.33%)
occurrences (all)	0	2	1
Abdominal pain			
subjects affected / exposed	1 / 12 (8.33%)	1 / 11 (9.09%)	1 / 30 (3.33%)
occurrences (all)	1	1	1
Vomiting			
subjects affected / exposed	1 / 12 (8.33%)	2 / 11 (18.18%)	1 / 30 (3.33%)
occurrences (all)	1	3	1
Ascites			
subjects affected / exposed	2 / 12 (16.67%)	1 / 11 (9.09%)	0 / 30 (0.00%)
occurrences (all)	4	1	0
Dry mouth			
subjects affected / exposed	0 / 12 (0.00%)	1 / 11 (9.09%)	0 / 30 (0.00%)
occurrences (all)	0	1	0
Abdominal pain upper			
subjects affected / exposed	1 / 12 (8.33%)	0 / 11 (0.00%)	0 / 30 (0.00%)
occurrences (all)	1	0	0
Dysphagia			
subjects affected / exposed	1 / 12 (8.33%)	0 / 11 (0.00%)	0 / 30 (0.00%)
occurrences (all)	1	0	0
Upper gastrointestinal haemorrhage			
subjects affected / exposed	1 / 12 (8.33%)	0 / 11 (0.00%)	0 / 30 (0.00%)
occurrences (all)	1	0	0

Hepatobiliary disorders			
Jaundice			
subjects affected / exposed	0 / 12 (0.00%)	1 / 11 (9.09%)	0 / 30 (0.00%)
occurrences (all)	0	1	0
Jaundice cholestatic			
subjects affected / exposed	0 / 12 (0.00%)	1 / 11 (9.09%)	0 / 30 (0.00%)
occurrences (all)	0	1	0
Skin and subcutaneous tissue disorders			
Pruritus			
subjects affected / exposed	0 / 12 (0.00%)	2 / 11 (18.18%)	3 / 30 (10.00%)
occurrences (all)	0	2	3
Rash			
subjects affected / exposed	2 / 12 (16.67%)	1 / 11 (9.09%)	2 / 30 (6.67%)
occurrences (all)	2	1	2
Dermatitis acneiform			
subjects affected / exposed	0 / 12 (0.00%)	1 / 11 (9.09%)	0 / 30 (0.00%)
occurrences (all)	0	1	0
Nail disorder			
subjects affected / exposed	0 / 12 (0.00%)	1 / 11 (9.09%)	0 / 30 (0.00%)
occurrences (all)	0	2	0
Acne			
subjects affected / exposed	0 / 12 (0.00%)	1 / 11 (9.09%)	0 / 30 (0.00%)
occurrences (all)	0	1	0
Perioral dermatitis			
subjects affected / exposed	0 / 12 (0.00%)	1 / 11 (9.09%)	0 / 30 (0.00%)
occurrences (all)	0	2	0
Rash erythematous			
subjects affected / exposed	0 / 12 (0.00%)	0 / 11 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Skin maceration			
subjects affected / exposed	0 / 12 (0.00%)	1 / 11 (9.09%)	0 / 30 (0.00%)
occurrences (all)	0	1	0
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	0 / 12 (0.00%)	4 / 11 (36.36%)	4 / 30 (13.33%)
occurrences (all)	0	4	5

Arthralgia			
subjects affected / exposed	0 / 12 (0.00%)	1 / 11 (9.09%)	2 / 30 (6.67%)
occurrences (all)	0	10	2
Pain in extremity			
subjects affected / exposed	0 / 12 (0.00%)	0 / 11 (0.00%)	2 / 30 (6.67%)
occurrences (all)	0	0	2
Myalgia			
subjects affected / exposed	1 / 12 (8.33%)	0 / 11 (0.00%)	1 / 30 (3.33%)
occurrences (all)	1	0	1
Muscular weakness			
subjects affected / exposed	0 / 12 (0.00%)	1 / 11 (9.09%)	0 / 30 (0.00%)
occurrences (all)	0	1	0
Infections and infestations			
Upper respiratory tract infection			
subjects affected / exposed	0 / 12 (0.00%)	0 / 11 (0.00%)	3 / 30 (10.00%)
occurrences (all)	0	0	3
Herpes zoster			
subjects affected / exposed	0 / 12 (0.00%)	0 / 11 (0.00%)	3 / 30 (10.00%)
occurrences (all)	0	0	4
Rash pustular			
subjects affected / exposed	0 / 12 (0.00%)	1 / 11 (9.09%)	0 / 30 (0.00%)
occurrences (all)	0	2	0
COVID-19			
subjects affected / exposed	1 / 12 (8.33%)	0 / 11 (0.00%)	0 / 30 (0.00%)
occurrences (all)	1	0	0
Urinary tract infection			
subjects affected / exposed	0 / 12 (0.00%)	0 / 11 (0.00%)	2 / 30 (6.67%)
occurrences (all)	0	0	3
Viral infection			
subjects affected / exposed	1 / 12 (8.33%)	0 / 11 (0.00%)	1 / 30 (3.33%)
occurrences (all)	1	0	1
Otitis media			
subjects affected / exposed	0 / 12 (0.00%)	1 / 11 (9.09%)	0 / 30 (0.00%)
occurrences (all)	0	1	0
Sinusitis			

subjects affected / exposed	0 / 12 (0.00%)	0 / 11 (0.00%)	1 / 30 (3.33%)
occurrences (all)	0	0	1
Candida infection			
subjects affected / exposed	0 / 12 (0.00%)	0 / 11 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	1 / 12 (8.33%)	4 / 11 (36.36%)	3 / 30 (10.00%)
occurrences (all)	1	4	3
Hyperkalaemia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 11 (0.00%)	1 / 30 (3.33%)
occurrences (all)	0	0	5
Hypocalcaemia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 11 (0.00%)	3 / 30 (10.00%)
occurrences (all)	0	0	3
Hyponatraemia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 11 (0.00%)	1 / 30 (3.33%)
occurrences (all)	0	0	2
Diabetes mellitus			
subjects affected / exposed	0 / 12 (0.00%)	1 / 11 (9.09%)	0 / 30 (0.00%)
occurrences (all)	0	1	0
Hypokalaemia			
subjects affected / exposed	1 / 12 (8.33%)	0 / 11 (0.00%)	2 / 30 (6.67%)
occurrences (all)	2	0	2
Hypophosphataemia			
subjects affected / exposed	0 / 12 (0.00%)	1 / 11 (9.09%)	0 / 30 (0.00%)
occurrences (all)	0	1	0
Hyperglycaemia			
subjects affected / exposed	1 / 12 (8.33%)	0 / 11 (0.00%)	1 / 30 (3.33%)
occurrences (all)	2	0	1

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
17 May 2021	The overall rationale for this amendment is to correct a typographical error in the page footer.
28 February 2022	The following main changes were implemented: update of Medical Monitor contact information following change in personnel; clarification that one or more recommended phase 2 doses (RP2Ds) may be selected; removal of Response Assessment in Neuro-Oncology criteria; clarification of requirement for pre-screening to determine eligibility by EGFR testing; clarification on the conduct and design of Phase 1; specification of the starting dose for the study based on information from the ongoing AFM24-101 study; clarification that that if any of the stopping rules applicable to the expansion phase is met, enrolment in Phase 2a can restart only after approval of a substantial amendment by the regulatory authority; EXP-4 will no longer be included for enrollment in this study and was removed globally; clarification on COVID-19 vaccinations policy; update to exclusion and inclusion criteria; clarification of premedication requirements and addition of pre-medication guidance for split-day dosing; clarification of AFM24 administration details; addition of most current half-life information for AFM24; clarification on pre-screening; revision that survival status should be collected until withdrawal of consent, death, or the end of the study; clarification of instructions for dose interruptions, delays, modification and discontinuations for AFM24 treatment; clarification of the drugs that are prohibited from use during the study; alignment of guidance for management of atezolizumab-related toxicities based on the current Summary of Product Characteristics; updates to the guidance on management of AEs and drug dose modification or discontinuation; clarification of timing and instructions for AE collection; clarification the method and timing for reporting of Serious AEs and AE of Special Interest; changes to the schedule of assessments; addition of laboratory tests.
10 May 2023	The following main changes were implemented: update of study centers; addition of DCR as a secondary endpoint; addition of EXP-4; addition of the involvement of an IDMC to monitor safety throughout Phase 2a; update to inclusion and exclusion criteria; modification of the definition of AFM24 infusions being well tolerated from no IRR/cytokine release syndrome (CRS) Grade >1 to no IRR/CRS Grade >2; clarification on interim analyses performed during the trial; revision of indication for atezolizumab according to the updated Prescribing Information (USPI); inclusion of results from AFM24-101; addition of the rationale for selection of the monotherapy AFM24 RP2D from AFM24-101 study; clarification of the duration of Phase 2a; clarification of study procedures timepoints; addition of optional biopsies for confirmation of disease response/progression and could also be utilized for analysis of immunological and other effects of the drugs on the tumor microenvironment; streamlined safety management section to align and for consistency with Sponsor’s other programs; clarification of timing for collection of AEs and Serious AEs; update to laboratory tests.

09 December 2024	The following main changes were implemented: addition of three new expansion cohorts to Phase 2a portion of the study; update of premedication and instructions; revision of post-infusion monitoring requirements for subjects; update of inclusion and exclusion criteria; closing of cohorts EXP-2, EXP-3, and EXP-4 to recruitment; clarification of the pre-screening and re-screening processes; clarification of the minimum amount of AFM24 to be received by subjects to be eligible to continue in the study; revision of stopping rules; update of AFM24 monitoring to reflect the current safety data for AFM24 administration; clarification of time points of study procedures; update of definition of the full analysis set; addition of PPS; update of the definition of disease control rate; clarification of the approach for the use of interim analyses for the experimental and exploratory cohorts; clarification of mechanism of reporting of AEs and handling of related AEs to authorized auxiliary medicinal products (AxMPs) to ensure consistency across sites; update to the reporting period of Serious AEs; addition of information on personal data breach notification and assessment; update of the EU Regulations from Directive 2001/20/EC to 563/2014; update of subjects privacy information.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

This trial was prematurely discontinued due to the financial situation of the sponsor, and not for safety or efficacy reasons.

Notes: